However, IV administration achieves close to 100% bioavailability because it bypasses the digestive system entirely
So, all the more reason not to fall B12-deficient in the first place
BPC 157 angiogenesis and VEGFR2 model study
Separate Vials lets BPC-157 and TB-500 run on independent schedules daily BPC-157 with twice-weekly TB-500 loading
Clinical Evidence in Humans The topical evidence base is unusually robust for a research peptide: Facial aging study (71 women, 12 weeks): A GHK-Cu facial cream documented increased skin density and thickness, reduced laxity, improved clarity, and reduced fine lines and depth of wrinkles (PMID 26236730)
What to Expect Over Time In the first 710 days, users often describe subtle improvements in digestion, reduced soreness, or faster bounce-back after physical activity